Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Glivec in chronic phase CML patients untreated with interferon alfa
2017-001804-31Phase 3
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of imatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoints: Overall survival and Duration of chronic phase.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2017-001804-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001804-31.